Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016149116 - ANTIBODIES TARGETING S100B AND METHODS OF USE

Publication Number WO/2016/149116
Publication Date 22.09.2016
International Application No. PCT/US2016/022104
International Filing Date 11.03.2016
IPC
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 49/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08characterised by the carrier
10Organic compounds
14Peptides, e.g. proteins
A61K 49/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
06Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08characterised by the carrier
10Organic compounds
14Peptides, e.g. proteins
16Antibodies; Immunoglobulins; Fragments thereof
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 47/646
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
646the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
C07K 2317/34
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
G01N 2333/4727
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4727Calcium binding proteins, e.g. calmodulin
Applicants
  • UNIVERSITY OF MARYLAND, BALTIMORE [US]/[US] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • ZIMMER, Danna [US]/[US] (US)
  • MCINTUSH, Eric W. [US]/[US] (US)
  • CARWILE, Henry F. [US]/[US] (US)
  • CARWILE, John M. [US]/[US] (US)
Inventors
  • ZIMMER, Danna
  • MCINTUSH, Eric W.
  • CARWILE, Henry F.
  • CARWILE, John M.
Agents
  • HISSONG, Drew
Priority Data
62/132,97513.03.2015US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES TARGETING S100B AND METHODS OF USE
(FR) ANTICORPS CIBLANT LA PROTÉINE S100B ET PROCÉDÉS D'UTILISATION
Abstract
(EN)
Novel antibodies that exhibit binding specificity for S100B are disclosed, as well as variants and fragments thereof that retain the binding specificity of the antibodies from which they are derived, collectively termed S100B binding agents. Methods of using these antibodies in the treatment and prevention of S100B-associated diseases are also provided. Methods of using these antibodies in the screening and diagnosis of subjects for S100B-associated diseases are further provided.
(FR)
L'invention concerne de nouveaux anticorps qui présentent une spécificité de liaison pour la protéine S100B, ainsi que des variantes et des fragments de ceux-ci qui conservent la spécificité de liaison des anticorps à partir desquels ils sont dérivés, collectivement appelés agents de liaison S100B. L'invention concerne également des procédés d'utilisation desdits anticorps dans le traitement et la prévention de maladies associées à la S100B. L'invention concerne également des procédés d'utilisation desdits anticorps dans le dépistage et le diagnostic de maladies associées à la S100B chez des sujets.
Latest bibliographic data on file with the International Bureau